After a back and forth with two potential buyers, bluebird bio has completed its sale to funds managed by global investment ...

Investment firms The Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners, together with Beacon Parent Holdings, L.P., have ...

Carlyle and SK Capital have provided significant primary capital to support and scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia ...

(“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

“The bluebird Board considered all reasonable alternatives during its review of strategic alternatives and concluded that the proposed transaction with Carlyle and SK Capital is the only viable ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene ...

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and SK Capital Partners for around $29 million – less than half its ...

HOUSTON, Oct 4 (Reuters) - Private equity firm SK Capital Partners acquired U.S. oilfield waste services firm Milestone Environmental Services from Amberjack Capital Partners for an undisclosed ...

SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of ...

SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, specialty materials, and ingredients sectors. The firm seeks to build resilient, sustainable ...